Beyond PEG: Emerging Polymer Lipid Alternatives for Lipid Nanoparticle (LNP) Formulations
Advanced Science · 2026-09 · 13 (50)
DOI: 10.1002/advs.77145 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Science, online erschienen am 12.08.2026. Verfasst von Zihnil A I Mazrad und 4 weiteren Autor:innen. Beteiligte Einrichtung: Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia. Hauptthemen laut MEDLINE: Polyethylene Glycols, Nanoparticles, Lipids, Polymers. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Australian Research Council, Australian Government MRFF, National Health and Medical Research Council.
Abstract (Originalsprache)
Lipid nanoparticles (LNPs) have rapidly emerged as the leading delivery platform for nucleic acid therapeutics due to their high encapsulation efficiency, scalable manufacturing, and clinical success in siRNA and mRNA medicines. Poly(ethylene glycol)‐lipids ((PEG)–lipids) have been central to this progress by providing steric stabilization, size control, and tunable biodistribution. However, PEGylation also introduces important limitations, including complement activation, pre‐existing and treatment‐induced anti‐PEG antibodies, and accelerated blood clearance, which increasingly constrain repeated and long‐term dosing strategies. This review focuses on recent advances in PEG‐alternative LNP designs, including non‐PEG polymers, zwitterionic and biomimetic lipids, polypeptides, and structurally modified PEG analogues. We compare how polymer chemistry, anchor geometry, and grafting architecture influence LNP formation, physicochemical properties, biodistribution, cellular uptake, and immunological outcomes. Moreover, we discuss key challenges that remain in translating PEG‐free and PEG‐modified LNPs toward clinical application and propose future directions to better understand in vivo behavior and enable rational design of next‐generation stealth LNPs. Overall, PEG lipid alternatives should not be viewed as simple PEG mimics, but as distinct surface‐engineering materials that create new nano‐bio interfaces and reshape LNP behavior in biological systems.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
- Materials Science and Engineering, Monash University, Clayton, Victoria, Australia.
- Olivia Newton-John Cancer Research Institute, and School of Cancer Medicine, La Trobe University, Heidelberg, Victoria, Australia.
- Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia.
- Melbourne Sexual Health Centre and Department of Infectious Diseases, Alfred Hospital and Central Clinical School, Monash University, Melbourne, Victoria, Australia.
ORCID-Profile: Yi Ju, Stephen J Kent, Kristian Kempe
Förderung
- Australian Research Council
- Australian Government MRFF
- National Health and Medical Research Council
Zitieren
APA
Mazrad, Z. A. I., Ju, Y., Kent, S. J., Pouton, C. W., & Kempe, K. (2026). Beyond PEG: Emerging Polymer Lipid Alternatives for Lipid Nanoparticle (LNP) Formulations. Advanced Science, 13(50). https://doi.org/10.1002/advs.77145
Vancouver
Mazrad ZAI, Ju Y, Kent SJ, Pouton CW, Kempe K. Beyond PEG: Emerging Polymer Lipid Alternatives for Lipid Nanoparticle (LNP) Formulations. Advanced Science. 2026;13(50). doi:10.1002/advs.77145
BibTeX
@article{Mazrad2026,
author = {Mazrad, Zihnil A I and Ju, Yi and Kent, Stephen J and Pouton, Colin W and Kempe, Kristian},
title = {Beyond PEG: Emerging Polymer Lipid Alternatives for Lipid Nanoparticle (LNP) Formulations},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {50},
doi = {10.1002/advs.77145}
}
EUVIMED